Furthermore, due to our data, based on a prolonged follow-up, show that the rates of relapse are still disappointing for both patients with inv(16) AML and those with t(8;21) AML, it is important that future studies identify and target therapeutically the leukemogenic mechanisms accountable for molecular and clinical differences between the two cytogenetic groups of CBF AML. Here, CEBPZ is linked to acute myeloid leukemia.